87776-80-5

Upstream product

• 75-21-8 oxirane 
• 89980-68-7 3,4-dimethylphenylmagnesium bromide 
• 105401-66-9 acetic acid-(3,4-dimethyl-phenethyl ester) 
• 583-71-1 4-bromo-o-xylene 
• 57486-71-2 2-(3,4-dimethylphenyl)acetic acid methyl ester 
• 3020-06-2 3,4-dimethylphenylacetonitrile 
• 102-46-5 4-(chloromethyl)-1,2-dimethylbenzene 
• 95-47-6 o-xylene 
• 17283-16-8 3,4-dimethylphenylacetic acid 

Downstream Products

• 93407-04-6 phenyl-carbamic acid-(3,4-dimethyl-phenethyl ester) 
• 105907-98-0 5-<3,4-Dimethyl-phenyl>-3-thia-valeriansaeurechlorid 
• 110530-91-1 2,2'-Bis-<3,4-dimethyl-phenyl>-diethylsulfid 
• 105972-06-3 5-<3,4-Dimethyl-phenyl>-3-thia-valeriansaeureamid 
• 857169-78-9 5-<3,4-Dimethyl-phenyl>-3-thia-valeriansaeure 
• 103440-42-2 2-<3,4-Dimethyl-phenyl>-ethylmercaptan 
• 503597-14-6 N-[4-(3,4-dimethylphenyl)-2-(pivaloyloxymethyl)butyl]-N'-[3-methoxy-4-(methoxymethoxy)benzyl]thiourea 
• 503597-34-0 N-[4-(3,4-dimethylphenyl)-1-pivaloyloxy-2-butyl]-N'-[3-methoxy-4-(methoxymethoxy)benzyl]thiourea 
• 503597-26-0 ethyl 4-(3,4-dimethylphenyl)-2-[(diphenylmethylene)amino]butanoate 
• 503597-31-7 2-[(tert-butoxycarbonyl)amino]-4-(3,4-dimethylphenyl)butyl pivalate 
• 503597-28-2 ethyl 2-(tert-butoxycarbonylamino)-4-(3,4-dimethylphenyl)butanoate 
• 503597-11-3 2-(azidomethyl)-4-(3,4-dimethylphenyl)butyl pivalate 
• 503597-29-3 tert-butyl N-[3-(3,4-dimethylphenyl)-1-(hydroxymethyl)propyl]carbamate 
• 503598-02-5 2,2-dimethyl-propionic acid 2-aminomethyl-4-(3,4-dimethyl-phenyl)-butyl ester 

Relevant academic research and scientific papers

Catalytic Cyclization of o-Alkynyl Phenethylamines via Osmacyclopropene Intermediates: Direct Access to Dopaminergic 3-Benzazepines

A novel osmium-catalyzed cyclization of o-alkynyl phenethylamines to give 3-benzazepines is reported. The procedure allows the straightforward preparation of a broad range of dopaminergic 3-benzazepine derivatives. Mechanistic investigations revealed that the process takes place via osmacyclopropene intermediates, which were isolated and characterized by X-ray crystallography.

Structure-activity relationships of simplified resiniferatoxin analogues with potent VR1 agonism elucidates an active conformation of RTX for VR1 binding

We previously described a series of N-(3-acyloxy-2-benzylpropyl) homovanillate and N′-(4-hydroxy-3-methoxybenzyl) thiourea derivatives that were potent VR1 agonists with high-affinities and excellent analgesic profiles. The design of these simplified RTX analogues was based on our RTX-derived pharmacophore model which incorporates the 4-hydroxy-3- methoxyphenyl (A-region), C20-ester (B-region), orthophenyl (C1-region) and C3-keto (C2-region) groups of RTX. For the purpose of optimizing the spatial arrangement of the four principal pharmacophores on the lead agonists (1-4), we have modified the distances in the parent C-region, 3-acyloxy-2-benzylpropyl groups, by lengthening or shortening one carbon to vary the distances between the pharmacophores. We find that two of the amides, 4 and 19, possess EC50 values i) and calcium influx (EC50) values. The binding affinities of the agonists correlated best with the RMS values derived from RTX conformation E (r2=0.92), predicting a model of the active conformation of RTX and related vanilloids for binding to VR1. Poorer correlation was obtained between any of the conformations and the EC 50 values for calcium influx.

Muscarinic receptor antagonists

Muscarinic receptor antagonists of formula (I), and their pharmaceutically acceptable salts, wherein Y is --CH 2 --, --(CH 2) 2 --, --CH 2 O--, --(CH 2) 2 O-- or --CH 2 S--; R is --CH or --CONH 2 ; and R 1 is a group of formula (a), where R 2 and R 3 are each independently H, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, --(CH 2) n OH, halo, trifluoromethyl, cyano, --(CH 2) n NR 4 R 5, --CO(C 1 -C 4 alkyl), --OCO(C 1 -C 4 alkyl), --CH(OH)(C 1 -C 4 alkyl), --C(OH)(C 1 -C 4 alkyl 2, --SO 2 NH 2, --(CH 2) n CONR 6 R 7 or --(CH 2) n COO(C 1 -C 4 alkyl); R 4 is H or C 1 -C 4 alkyl; R 5 is H, C 1 -C 4 alkyl or C 1 -C 4 alkysulphonyl; R 6 and R 7 are each independently H or C 1 -C 4 alkyl; and n is 0, 1 or 2. The compounds are particularly useful in treating irritable bowel syndrome.